Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
Portfolio Pulse from
Vivos Therapeutics, Inc. held its Q3 2024 earnings call, discussing financial results and company performance. Key participants included CEO Kirk Huntsman and CFO Brad Amman.

November 15, 2024 | 4:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vivos Therapeutics, Inc. conducted its Q3 2024 earnings call, providing insights into its financial performance and strategic direction.
The earnings call is a routine event where Vivos Therapeutics discusses its quarterly financial results. While it provides important insights, the article does not specify any significant changes or surprises that would impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100